Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. NASDAQ DIP and RIP Message Board

$PTX BO in final stretch (translated) http://i

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 23076
Posted On: 08/24/2016 7:06:08 PM
Avatar
Posted By: nwar
$PTX BO in final stretch (translated)

http://intereconomia.com/empresas/la-venta-pe...60824-2144

I translated it. Not perfect but better than Google Translate.

=================================================

The sale of Pernix Therapeutics in the final stretch

The sale of the pharmaceutical Pernix Therapeutics Holdings, process opened by the company itself several months ago, enters its final stretch with a valuation that could total 500 million dollars. Sources close to Perella Weinberg Partners, who's acting as financial adviser in the operation, have pointed out that this operation can be closed even before next Monday. But also said that, in recent days, new suitors have appeared, including several US and European major pharmaceutical companies.

Initially, the most likely buyer was Concordia Internacioanal, but the auction has been opened to new companies and different rumors are circulating in the American Nasdaq about who will be the final buyer.

Pernix Therapeutics Holdings, was founded in 1996 in Morristown, New Jersey. It wasn't until 2010 that they were licensed as a pharmaceutical company. They specialize in the development of generic drugs. Their annual revenues exceed $ 175 million dollars. Many experts believe in the great potential of this market by the proven efficiency and safety of their marketed drugs which ensures stable and predictable income over time.

=================================================

Notes from Intereconomia: It's a media company from Spain that specializes in economy and markets. They have several publications and several radio stations. So, for me, the article looks formal and not just news or rumors from an independent investor.


(2)
(0)




IMHO

Always, always do you own DD. Only invest funds you can afford to lose and trust nobody but yourself.




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us